Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(50.0%)
Phase 4
1(25.0%)
Phase 2
1(25.0%)
4Total
N/A(2)
Phase 4(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT00411827Not ApplicableCompleted

Goblet Cell Response and Dry Eye Symptoms After PRK and LASIK

Role: collaborator

NCT03318874Phase 4Completed

Optimization of the Treatment of Dry Eye Disease Caused by Meibomian Gland Dysfunction

Role: collaborator

NCT03560765Not ApplicableTerminated

Mobile Electronic Devices for Visual Impairment

Role: collaborator

NCT00406991Phase 2Completed

Retinal Blood Flow and Microthrombi in Type 1 Diabetes

Role: lead

All 4 trials loaded